{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:43:56Z","timestamp":1790214236114,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:00:00Z","timestamp":1581033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81772990"],"award-info":[{"award-number":["81772990"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81572748"],"award-info":[{"award-number":["81572748"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013314","name":"\u201c111\u201d project","doi-asserted-by":"crossref","award":["111-2-12"],"award-info":[{"award-number":["111-2-12"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Free Exploration Program of Central South University","award":["2018zzts823"],"award-info":[{"award-number":["2018zzts823"]}]},{"name":"the Free Exploration Program of Central South University","award":["2018zzts233"],"award-info":[{"award-number":["2018zzts233"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>BRD7 is a tumor suppressor known to inhibit cell proliferation and cell cycle progression and initiate apoptosis in breast cancer. However, the function and underlying molecular events of BRD7 in tumor invasion and metastasis in breast cancer are not fully understood.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>BRD7 expression was assessed in two stable cell lines MDA231 and MCF7 with BRD7 overexpression and one stable cell line MDA231 with BRD7 interference using qRT-PCR and western blotting. CCK8 assay was used to examine the proliferation ability of MDA231 and MCF7 cells. Scratch wound healing assay was used to evaluate cell migration in MDA231 and MCF7 cells. Both Matrigel and three-dimensional invasion assays were performed to investigate the cell invasion ability after BRD7 overexpression or silencing or YB1 restoration in MDA231 and MCF7 cells. The potential interacting proteins of BRD7 were screened using co-immunoprecipitation combined with mass spectrometry and verified by co-immunoprecipitation in HEK293T cells. Additionally, we confirmed the specific binding region between BRD7 and YB1 in HEK293T cells by constructing a series of deletion mutants of BRD7 and YB1 respectively. Finally, xenograft and metastatic mouse models using MDA231 cells were established to confirm the effect of BRD7 on tumor growth and metastasis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Here, the results of a series of assays in vitro indicated that BRD7 has the ability to inhibit the mobility, migration and invasion of breast cancer cells. In addition, YB1 was identified as a novel interacting protein of BRD7, and BRD7 was found to associate with the C-terminus of YB1 via its N-terminus. BRD7 decreases the expression of YB1 through negatively regulating YB1 phosphorylation at Ser102, thereby promoting its proteasomal degradation. Furthermore, gene set enrichment analysis revealed that epithelial-mesenchymal transition (EMT) is the common change occurring with altered expression of either BRD7 or YB1 and that BRD7 represses mesenchymal genes and activates epithelial genes. Moreover, restoring the expression of YB1 antagonized the inhibitory effect of BRD7 on tumorigenicity, EMT, invasiveness and metastasis through a series of in\u00a0vitro and in vivo experiments. Additionally, BRD7 expression was negatively correlated with the level of YB1 in breast cancer patients. The combination of low BRD7 and high YB1 expression was significantly associated with poor prognosis, distant metastasis and advanced TNM stage.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Collectively, these findings uncover that BRD7 blocks tumor growth, migration and metastasis by negatively regulating YB1-induced EMT, providing new insights into the mechanism by which BRD7 contributes to the progression and metastasis of breast cancer.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13046-019-1493-4","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T00:06:38Z","timestamp":1581033998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["BRD7 suppresses invasion and metastasis in breast cancer by negatively regulating YB1-induced epithelial-mesenchymal transition"],"prefix":"10.1186","volume":"39","author":[{"given":"Weihong","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengna","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunchun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songqing","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiping","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,7]]},"reference":[{"key":"1493_CR1","doi-asserted-by":"publisher","first-page":"i89","DOI":"10.1093\/annonc\/mdq292","volume":"21","author":"P Savagner","year":"2010","unstructured":"Savagner P. The epithelial\u2013mesenchymal transition (EMT) phenomenon. Ann Oncol. 2010;21:i89\u201392.","journal-title":"Ann Oncol"},{"key":"1493_CR2","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nrc.2017.118","volume":"18","author":"T Brabletz","year":"2018","unstructured":"Brabletz T, Kalluri R, Nieto MA, Weinberg RA. EMT in cancer. Nat Rev Cancer. 2018;18:128\u201334.","journal-title":"Nat Rev Cancer"},{"key":"1493_CR3","first-page":"568","volume":"28","author":"YU Ying","year":"2001","unstructured":"Ying YU, Guo Z, Juan XJ, Hua LZ, Cheng ZB, Li C, et al. Coding-region single nucleotide polymorphisms in BRD7 gene and nasopharyngeal carcinoma Susceptiblity. Prog Biochem Biophys. 2001;28:568\u201372.","journal-title":"Prog Biochem Biophys"},{"key":"1493_CR4","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1158\/0008-5472.CAN-09-2089","volume":"70","author":"MT Harte","year":"2010","unstructured":"Harte MT, O'Brien GJ, Ryan NM, Gorski JJ, Savage KI, Crawford NT, et al. BRD7, a subunit of SWI\/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 2010;70:2538\u201347.","journal-title":"Cancer Res"},{"key":"1493_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.molcel.2014.02.016","volume":"54","author":"YH Chiu","year":"2014","unstructured":"Chiu YH, Lee JY, Cantley LC. BRD7, a tumor suppressor, interacts with p85alpha and regulates PI3K activity. Mol Cell. 2014;54:193\u2013202.","journal-title":"Mol Cell"},{"key":"1493_CR6","first-page":"742","volume":"8","author":"X Yu","year":"2016","unstructured":"Yu X, Li Z, Shen J. BRD7: a novel tumor suppressor gene in different cancers. Am J Transl Res. 2016;8:742\u20138.","journal-title":"Am J Transl Res"},{"key":"1493_CR7","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1158\/1538-7445.AM2018-2647","volume":"78","author":"CL Nigro","year":"2018","unstructured":"Nigro CL, Vivenza D, Garrone O, Brizio R, Mantovani F, Del Sal G, et al. Bromodomain-containing protein 7 (BRD7) is a candidate tumor suppressor in breast carcinoma and prognostic biomarker. Cancer Res. 2018;78:2647.","journal-title":"Cancer Res"},{"key":"1493_CR8","first-page":"1487","volume":"41","author":"J Ma","year":"2019","unstructured":"Ma J, Niu W, Wang X, Zhou Y, Wang H, Liu F, et al. Bromodomaincontaining protein 7 sensitizes breast cancer cells to paclitaxel by activating Bcl2antagonist\/killer protein. Oncol Rep. 2019;41:1487\u201396.","journal-title":"Oncol Rep"},{"key":"1493_CR9","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10456-017-9576-3","volume":"20","author":"JR van Beijnum","year":"2017","unstructured":"van Beijnum JR, Nowak-Sliwinska P, van Berkel M, Wong TJ, Griffioen AW. A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7). Angiogenesis. 2017;20:641\u201354.","journal-title":"Angiogenesis"},{"key":"1493_CR10","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/cmi.2016.31","volume":"14","author":"R Zhao","year":"2017","unstructured":"Zhao R, Liu Y, Wang H, Yang J, Niu W, Fan S, et al. BRD7 plays an anti-inflammatory role during early acute inflammation by inhibiting activation of the NF-small ka, CyrillicB signaling pathway. Cell Mol Immunol. 2017;14:830\u201341.","journal-title":"Cell Mol Immunol"},{"key":"1493_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan D, Kobayashi A, Jiang P, de Andrade LF, Tay RE, Luoma AM, et al. A major chromatin regulator determines resistance of tumor cells to T cell\u2013mediated killing. Science. 2018;359:770\u20135.","journal-title":"Science"},{"key":"1493_CR12","doi-asserted-by":"publisher","first-page":"e2156","DOI":"10.1038\/cddis.2016.64","volume":"7","author":"Y Liu","year":"2016","unstructured":"Liu Y, Zhao R, Wang H, Luo Y, Wang X, Niu W, et al. miR-141 is involved in BRD7-mediated cell proliferation and tumor formation through suppression of the PTEN\/AKT pathway in nasopharyngeal carcinoma. Cell Death Dis. 2016;7:e2156.","journal-title":"Cell Death Dis"},{"key":"1493_CR13","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11010-007-9466-x","volume":"303","author":"C Peng","year":"2007","unstructured":"Peng C, Liu HY, Zhou M, Zhang LM, Li XL, Shen SR, et al. BRD7 suppresses the growth of nasopharyngeal carcinoma cells (HNE1) through negatively regulating beta-catenin and ERK pathways. Mol Cell Biochem. 2007;303:141\u20139.","journal-title":"Mol Cell Biochem"},{"key":"1493_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/ncb2038","volume":"12","author":"J Drost","year":"2010","unstructured":"Drost J, Mantovani F, Tocco F, Elkon R, Comel A, Holstege H, et al. BRD7 is a candidate tumour suppressor gene required for p53 function. Nat Cell Biol. 2010;12:380\u20139.","journal-title":"Nat Cell Biol"},{"key":"1493_CR15","first-page":"e127682","volume":"10","author":"Z Xue","year":"2015","unstructured":"Xue Z, Zhao J, Niu L, An G, Guo Y, Ni L. Up-regulation of MiR-300 promotes proliferation and invasion of osteosarcoma by targeting BRD7. PLoS One. 2015;10:e127682.","journal-title":"PLoS One"},{"key":"1493_CR16","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/1078-0432.CCR-13-1271","volume":"20","author":"Y Park","year":"2014","unstructured":"Park Y, Lee J, Kim H, Lee Y, Kim T, Choi CH, et al. Tumor suppressive effects of Bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma. Clin Cancer Res. 2014;20:565\u201375.","journal-title":"Clin Cancer Res"},{"key":"1493_CR17","doi-asserted-by":"publisher","first-page":"4872","DOI":"10.1158\/0008-5472.CAN-05-3561","volume":"66","author":"J Wu","year":"2006","unstructured":"Wu J, Lee C, Yokom D, Jiang H, Cheang MC, Yorida E, et al. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. Cancer Res. 2006;66:4872\u20139.","journal-title":"Cancer Res"},{"key":"1493_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nm0497-447","volume":"3","author":"RC Bargou","year":"1997","unstructured":"Bargou RC, Jurchott K, Wagener C, Bergmann S, Metzner S, Bommert K, et al. Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med. 1997;3:447\u201350.","journal-title":"Nat Med"},{"key":"1493_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/wrna.1200","volume":"5","author":"DN Lyabin","year":"2014","unstructured":"Lyabin DN, Eliseeva IA, Ovchinnikov LP. YB-1 protein: functions and regulation. Wiley Interdiscip Rev RNA. 2014;5:95\u2013110.","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"1493_CR20","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ccr.2009.04.006","volume":"15","author":"G Mouneimne","year":"2009","unstructured":"Mouneimne G, Brugge JS. YB-1 translational control of epithelial-mesenchyme transition. Cancer Cell. 2009;15:357\u20139.","journal-title":"Cancer Cell"},{"key":"1493_CR21","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.18632\/oncotarget.1790","volume":"5","author":"MI Khan","year":"2014","unstructured":"Khan MI, Adhami VM, Lall RK, Sechi M, Joshi DC, Haidar OM, et al. YB-1 expression promotes epithelial-to-mesenchymal transition in prostate cancer that is inhibited by a small molecule fisetin. Oncotarget. 2014;5:2462\u201374.","journal-title":"Oncotarget"},{"key":"1493_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13046-018-0734-2","volume":"37","author":"Y Liu","year":"2018","unstructured":"Liu Y, Zhao R, Wei Y, Li M, Wang H, Niu W, et al. BRD7 expression and c-Myc activation forms a double-negative feedback loop that controls the cell proliferation and tumor growth of nasopharyngeal carcinoma by targeting oncogenic miR-141. J Exp Clin Cancer Res. 2018;37:64.","journal-title":"J Exp Clin Cancer Res"},{"key":"1493_CR23","doi-asserted-by":"publisher","first-page":"4153","DOI":"10.1073\/pnas.1703931114","volume":"114","author":"ES Sokol","year":"2017","unstructured":"Sokol ES, Feng YX, Jin DX, Tizabi MD, Miller DH, Cohen MA, et al. SMARCE1 is required for the invasive progression of in situ cancers. Proc Natl Acad Sci U S A. 2017;114:4153\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1493_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/bjc.2017.385","volume":"118","author":"F Wei","year":"2018","unstructured":"Wei F, Wu Y, Tang L, He Y, Shi L, Xiong F, et al. BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM. Br J Cancer. 2018;118:233\u201347.","journal-title":"Br J Cancer"},{"key":"1493_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.neo.2017.05.002","volume":"19","author":"DS Chandrashekar","year":"2017","unstructured":"Chandrashekar DS, Bashel B, Balasubramanya S, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19:649\u201358.","journal-title":"Neoplasia"},{"key":"1493_CR26","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10549-009-0674-9","volume":"123","author":"B Gyorffy","year":"2010","unstructured":"Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 2010;123:725\u201331.","journal-title":"Breast Cancer Res Treat"},{"key":"1493_CR27","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/bies.10300","volume":"25","author":"K Kohno","year":"2003","unstructured":"Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays. 2003;25:691\u20138.","journal-title":"Bioessays"},{"key":"1493_CR28","doi-asserted-by":"publisher","first-page":"4281","DOI":"10.1038\/sj.onc.1208590","volume":"24","author":"BW Sutherland","year":"2005","unstructured":"Sutherland BW, Kucab J, Wu J, Lee C, Cheang MCU, Yorida E, et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene. 2005;24:4281\u201392.","journal-title":"Oncogene"},{"key":"1493_CR29","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1128\/MCB.26.1.277-292.2006","volume":"26","author":"V Evdokimova","year":"2006","unstructured":"Evdokimova V, Ruzanov P, Anglesio MS, Sorokin AV, Ovchinnikov LP, Buckley J, et al. Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species. Mol Cell Biol. 2006;26:277\u201392.","journal-title":"Mol Cell Biol"},{"key":"1493_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/0008-5472.CAN-13-2466","volume":"74","author":"K Wu","year":"2014","unstructured":"Wu K, Chen K, Wang C, Jiao X, Wang L, Zhou J, et al. Cell fate factor DACH1 represses YB-1-mediated oncogenic transcription and translation. Cancer Res. 2014;74:829\u201339.","journal-title":"Cancer Res"},{"key":"1493_CR31","doi-asserted-by":"publisher","first-page":"4638","DOI":"10.1158\/1078-0432.CCR-12-3705","volume":"19","author":"K Imada","year":"2013","unstructured":"Imada K, Shiota M, Kohashi K, Kuroiwa K, Song Y, Sugimoto M, et al. Mutual regulation between Raf\/MEK\/ERK signaling and Y-box-binding protein-1 promotes prostate cancer progression. Clin Cancer Res. 2013;19:4638\u201350.","journal-title":"Clin Cancer Res"},{"key":"1493_CR32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/0272-6386(95)90610-X","volume":"26","author":"ED Hay","year":"1995","unstructured":"Hay ED, Zuk A. Transformations between epithelium and mesenchyme: normal, pathological, and experimentally induced. Am J Kidney Dis. 1995;26:678\u201390.","journal-title":"Am J Kidney Dis"},{"key":"1493_CR33","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1245\/ASO.2005.04.010","volume":"12","author":"TA Martin","year":"2005","unstructured":"Martin TA, Goyal A, Watkins G, Jiang WG. Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005;12:488\u201396.","journal-title":"Ann Surg Oncol"},{"key":"1493_CR34","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer. 2007;7:415\u201328.","journal-title":"Nat Rev Cancer"},{"key":"1493_CR35","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","volume":"102","author":"Y Wu","year":"2010","unstructured":"Wu Y, Zhou BP. TNF-alpha\/NF-kappaB\/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639\u201344.","journal-title":"Br J Cancer"},{"key":"1493_CR36","doi-asserted-by":"publisher","first-page":"35516","DOI":"10.1074\/jbc.M303920200","volume":"278","author":"A Lasham","year":"2003","unstructured":"Lasham A, Moloney S, Hale T, Homer C, Zhang YF, Murison JG, et al. The Y-box-binding protein, YB1, is a potential negative regulator of the p53 tumor suppressor. J Biol Chem. 2003;278:35516\u201323.","journal-title":"J Biol Chem"},{"key":"1493_CR37","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.1128\/MCB.25.11.4625-4637.2005","volume":"25","author":"ZH Lu","year":"2005","unstructured":"Lu ZH, Books JT, Ley TJ. YB-1 is important for late-stage embryonic development, optimal cellular stress responses, and the prevention of premature senescence. Mol Cell Biol. 2005;25:4625\u201337.","journal-title":"Mol Cell Biol"},{"key":"1493_CR38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jprot.2012.08.019","volume":"77","author":"SP Somasekharan","year":"2012","unstructured":"Somasekharan SP, Stoynov N, Rotblat B, Leprivier G, Galpin JD, Ahern CA, et al. Identification and quantification of newly synthesized proteins translationally regulated by YB-1 using a novel click-SILAC approach. J Proteome. 2012;77:e1\u201310.","journal-title":"J Proteome"},{"key":"1493_CR39","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.febslet.2013.02.047","volume":"587","author":"JH Shi","year":"2013","unstructured":"Shi JH, Zheng B, Li YH, Sun Y, Han AL, Zhang XH, et al. Novel insight into Y-box binding protein 1 in the regulation of vascular smooth muscle cell proliferation through targeting GC box-dependent genes. FEBS Lett. 2013;587:1326\u201332.","journal-title":"FEBS Lett"},{"key":"1493_CR40","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.ccr.2009.03.017","volume":"15","author":"V Evdokimova","year":"2009","unstructured":"Evdokimova V, Tognon C, Ng T, Ruzanov P, Melnyk N, Fink D, et al. Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. Cancer Cell. 2009;15:402\u201315.","journal-title":"Cancer Cell"},{"key":"1493_CR41","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1158\/0008-5472.CAN-18-0222","volume":"78","author":"W Su","year":"2018","unstructured":"Su W, Feng S, Chen X, Yang X, Mao R, Guo C, et al. Silencing of long noncoding RNA MIR22HG triggers cell survival\/death signaling via oncogenes YBX1, MET, and p21 in lung cancer. Cancer Res. 2018;78:3207\u201319.","journal-title":"Cancer Res"},{"key":"1493_CR42","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/cas.14006","volume":"110","author":"M Kuwano","year":"2019","unstructured":"Kuwano M, Shibata T, Watari K, Ono M. Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer. Cancer Sci. 2019;110:1536\u201343.","journal-title":"Cancer Sci"},{"key":"1493_CR43","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1016\/j.febslet.2006.06.023","volume":"580","author":"M Lutz","year":"2006","unstructured":"Lutz M, Wempe F, Bahr I, Zopf D, von Melchner H. Proteasomal degradation of the multifunctional regulator YB-1 is mediated by an F-Box protein induced during programmed cell death. FEBS Lett. 2006;580:3921\u201330.","journal-title":"FEBS Lett"},{"key":"1493_CR44","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jmb.2008.09.060","volume":"384","author":"M Chibi","year":"2008","unstructured":"Chibi M, Meyer M, Skepu A, Rees DJG, Moolman-Smook JC, Pugh DJ. RBBP6 interacts with multifunctional protein YB-1 through its RING finger domain, leading to ubiquitination and proteosomal degradation of YB-1. J Mol Biol. 2008;384:908\u201316.","journal-title":"J Mol Biol"},{"key":"1493_CR45","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/ncb1110","volume":"6","author":"E Yeh","year":"2004","unstructured":"Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308\u201318.","journal-title":"Nat Cell Biol"},{"key":"1493_CR46","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","volume":"22","author":"F Luciano","year":"2003","unstructured":"Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G, et al. Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003;22:6785\u201393.","journal-title":"Oncogene"},{"key":"1493_CR47","first-page":"49","volume":"2","author":"J Wu","year":"2007","unstructured":"Wu J, Stratford AL, Astanehe A, Dunn SE. YB-1 is a transcription\/translation factor that orchestrates the oncogenome by hardwiring signal transduction to gene expression. Transl Oncogenomics. 2007;2:49\u201365.","journal-title":"Transl Oncogenomics"},{"key":"1493_CR48","doi-asserted-by":"publisher","first-page":"R86","DOI":"10.1186\/bcr2156","volume":"10","author":"G Habibi","year":"2008","unstructured":"Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res. 2008;10:R86.","journal-title":"Breast Cancer Res"},{"key":"1493_CR49","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s12282-015-0625-8","volume":"23","author":"A Lee","year":"2016","unstructured":"Lee A, Woo J, Park H, Sung SH, Seoh JY, Lim W, et al. The value of cytoplasmic Y-box-binding protein 1 as a prognostic marker for breast cancer in Korean. Breast Cancer-Tokyo. 2016;23:685\u201391.","journal-title":"Breast Cancer-Tokyo"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1493-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13046-019-1493-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1493-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T17:39:53Z","timestamp":1665769193000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1493-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,7]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1493"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1493-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,7]]},"assertion":[{"value":"4 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Ethics Review Committees\/Institutional Review Boards of Central South University (Changsha, China). And all the animal experiments in this study were approved by the Institutional Animal Care and Use Committee (IACUC) of central south university (Changsha, China). Clinical samples of breast cancer and normal breast samples were all collected from the Second Xiangya Hospital of Central South University. All patients involved in this article signed informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to submit the article for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30"}}